Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma.

doi:10.1097/HEP.0000000000001185

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma.

Hepatology (Baltimore, Md.) - 1 Sept 2025

Zabransky Daniel J, Kartalia Emma, Lee Jae W, Leatherman James M, Charmsaz Soren, Young Sara E, Chhabra Yash, Franch-Expósito Sebastià, Kang Martin, Maru Saumya, Rastkari Noushin, Davis Michael, Dalton William Brian, Oshima Kiyoko, Baretti Marina, Azad Nilofer S, Jaffee Elizabeth M, Yarchoan Mark

Abstract excerpt

BACKGROUND AND AIMS: Isocitrate dehydrogenase 1 ( IDH1 )-mutant cholangiocarcinoma (CCA) is a highly lethal subtype of hepatobiliary cancer that is often resistant to immune checkpoint inhibitor therapies. We evaluated the effects of IDH1 mutations in CCA cells on the tumor immune microenvironment and identified opportunities for therapeutic intervention. APPROACH AND RESULTS: Analysis of 2606 human CCA tumors...

Read the complete abstract on PubMed

Topics

Isocitrate Dehydrogenase
Cholangiocarcinoma
Animals
Mice
Humans

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Bile Duct Neoplasms

Tumor Microenvironment

Chemokine CCL2

Mutation

Cell Line, Tumor

Tumor-Associated Macrophages

CD8-Positive T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 39626209
DOI: 10.1097/HEP.0000000000001185
PMCID: PMC12130352

Genes

IDH1
CCL2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma.PMID 39626209Read ↗

Biology of IDH mutant cholangiocarcinoma.Semantic proximity Read ↗

Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.Semantic proximity Read ↗

Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma.Semantic proximity Read ↗

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors.Semantic proximity Read ↗

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.Semantic proximity Read ↗

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.Semantic proximity Read ↗

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies.Semantic proximity Read ↗

The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel ImmunotherapiesSemantic proximity Read ↗

IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic TargetingSemantic proximity Read ↗

Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.